Recruiting
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis - IM011-1105
Zaktualizowano:
14 grudzień, 2023
|
ClinicalTrials.gov
Płeć
Zakres wieku
Lokalizacje
Recruiting
Inclusion Criteria: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: - Currently participating in an interventional clinical trial (does not include observational registry or study)